Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | B3GNT2 | Q9NY97 | 3/20 | 0.42 |
| ▸ | ACSS2 | Q9NR19 | 12/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | F2R | P25116 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL989513 | 1.00 | PI4KB (0.46) | PI4KBNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL991367 | 1.00 | PI4KB (0.46) | PI4KBNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL990104 | 0.81 | B3GNT2 (0.43) | NPC1RAB9AB3GNT2ACSS2KDM4E | |
| SCHEMBL990105 | 0.81 | B3GNT2 (0.43) | NPC1RAB9AB3GNT2ACSS2KDM4E | |
| SCHEMBL989186 | 0.81 | ACSS2 (0.48) | PI4KBNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL11008032 | 0.78 | PI4KB (0.50) | PI4KBNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL5984668 | 0.78 | ACSS2 (0.45) | PI4KBNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL4837467 | 0.77 | PI4KB (0.74) | PI4KB | |
| SCHEMBL4581653 | 0.77 | NOS2 (0.49) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL4581651 | 0.77 | NOS2 (0.49) | NPC1RAB9ASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863310-B2 | Kinase inhibitors | ELI LILLY AND COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-20080227839-A1 | Kinase Inhibitors | ELI LILLY AND COMPANY | 2008-09-18 | — | — | US | disclosed |
| EP-1720862-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005080380-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227839-A1 | Kinase Inhibitors | ABL1, MAP3K20, MAP3K19 | PI4KB 62/4885NPC1 2472/4885RAB9A 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.